vs
百利高（PRGO）与UGI CORP（UGI）财务数据对比。点击上方公司名可切换其他公司
UGI CORP的季度营收约是百利高的1.9倍（$2.1B vs $1.1B），UGI CORP净利率更高（14.4% vs -127.8%，领先142.2%），UGI CORP同比增速更快（3.9% vs -2.5%），百利高自由现金流更多（$148.6M vs $-155.0M），过去两年百利高的营收复合增速更高（1.3% vs -7.5%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
UGI公司是总部位于美国宾夕法尼亚州普鲁士王市的能源企业，主营天然气与电力配送业务，布局覆盖范围广泛，在美国本土及欧洲地区均拥有成熟运营网络，为当地用户提供稳定可靠的能源配送服务。
PRGO vs UGI — 直观对比
营收规模更大
UGI
是对方的1.9倍
$1.1B
营收增速更快
UGI
高出6.4%
-2.5%
净利率更高
UGI
高出142.2%
-127.8%
自由现金流更多
PRGO
多$303.6M
$-155.0M
两年增速更快
PRGO
近两年复合增速
-7.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $2.1B |
| 净利润 | $-1.4B | $297.0M |
| 毛利率 | 32.6% | — |
| 营业利润率 | -116.0% | 22.0% |
| 净利率 | -127.8% | 14.4% |
| 营收同比 | -2.5% | 3.9% |
| 净利润同比 | -3093.9% | -20.8% |
| 每股收益（稀释后） | $-10.23 | $1.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOUGI
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $1.0B | $2.6B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | $1.4B | ||
| Q1 24 | $1.1B | $2.4B |
净利润PRGOUGI
| Q4 25 | $-1.4B | $297.0M | ||
| Q3 25 | $7.5M | $-13.0M | ||
| Q2 25 | $-8.4M | $-163.0M | ||
| Q1 25 | $-6.4M | $479.0M | ||
| Q4 24 | $-44.4M | $375.0M | ||
| Q3 24 | $-21.0M | $-273.0M | ||
| Q2 24 | $-108.4M | $-48.0M | ||
| Q1 24 | $2.0M | $496.0M |
毛利率PRGOUGI
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — | ||
| Q1 24 | 33.1% | — |
营业利润率PRGOUGI
| Q4 25 | -116.0% | 22.0% | ||
| Q3 25 | 7.0% | 1.1% | ||
| Q2 25 | 4.3% | -6.8% | ||
| Q1 25 | 4.5% | 26.6% | ||
| Q4 24 | 10.0% | 24.5% | ||
| Q3 24 | 7.4% | -20.4% | ||
| Q2 24 | -2.5% | 5.0% | ||
| Q1 24 | -5.1% | 29.7% |
净利率PRGOUGI
| Q4 25 | -127.8% | 14.4% | ||
| Q3 25 | 0.7% | -1.1% | ||
| Q2 25 | -0.8% | -12.0% | ||
| Q1 25 | -0.6% | 18.2% | ||
| Q4 24 | -3.9% | 18.9% | ||
| Q3 24 | -1.9% | -22.6% | ||
| Q2 24 | -10.2% | -3.6% | ||
| Q1 24 | 0.2% | 20.6% |
每股收益（稀释后）PRGOUGI
| Q4 25 | $-10.23 | $1.34 | ||
| Q3 25 | $0.05 | $-0.08 | ||
| Q2 25 | $-0.06 | $-0.76 | ||
| Q1 25 | $-0.05 | $2.19 | ||
| Q4 24 | $-0.32 | $1.74 | ||
| Q3 24 | $-0.15 | $-1.26 | ||
| Q2 24 | $-0.79 | $-0.23 | ||
| Q1 24 | $0.01 | $2.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $251.0M |
| 总债务越低越好 | — | $6.0B |
| 股东权益账面价值 | $2.9B | $5.0B |
| 总资产 | $8.5B | $15.8B |
| 负债/权益比越低杠杆越低 | — | 1.19× |
8季度趋势，按日历期对齐
现金及短期投资PRGOUGI
| Q4 25 | — | $251.0M | ||
| Q3 25 | $432.1M | $335.0M | ||
| Q2 25 | $454.2M | $350.0M | ||
| Q1 25 | $409.9M | $426.0M | ||
| Q4 24 | $558.8M | $240.0M | ||
| Q3 24 | $1.5B | $213.0M | ||
| Q2 24 | $542.8M | $183.0M | ||
| Q1 24 | $658.5M | $263.0M |
总债务PRGOUGI
| Q4 25 | — | $6.0B | ||
| Q3 25 | — | $6.5B | ||
| Q2 25 | — | $5.7B | ||
| Q1 25 | — | $6.6B | ||
| Q4 24 | — | $6.6B | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.3B | ||
| Q1 24 | — | $6.7B |
股东权益PRGOUGI
| Q4 25 | $2.9B | $5.0B | ||
| Q3 25 | $4.4B | $4.8B | ||
| Q2 25 | $4.5B | $4.9B | ||
| Q1 25 | $4.4B | $5.0B | ||
| Q4 24 | $4.3B | $4.6B | ||
| Q3 24 | $4.6B | $4.3B | ||
| Q2 24 | $4.5B | $4.7B | ||
| Q1 24 | $4.7B | $4.8B |
总资产PRGOUGI
| Q4 25 | $8.5B | $15.8B | ||
| Q3 25 | $10.1B | $15.5B | ||
| Q2 25 | $10.1B | $15.4B | ||
| Q1 25 | $9.8B | $15.7B | ||
| Q4 24 | $9.6B | $15.4B | ||
| Q3 24 | $11.2B | $15.1B | ||
| Q2 24 | $10.4B | $15.1B | ||
| Q1 24 | $10.6B | $15.6B |
负债/权益比PRGOUGI
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.32× | ||
| Q4 24 | — | 1.44× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | — | 1.34× | ||
| Q1 24 | — | 1.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $66.0M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $-155.0M |
| 自由现金流率自由现金流/营收 | 13.4% | -7.5% |
| 资本支出强度资本支出/营收 | 2.4% | 10.7% |
| 现金转化率经营现金流/净利润 | — | 0.22× |
| 过去12个月自由现金流最近4个季度 | $145.1M | $282.0M |
8季度趋势，按日历期对齐
经营现金流PRGOUGI
| Q4 25 | $175.4M | $66.0M | ||
| Q3 25 | $51.7M | $90.0M | ||
| Q2 25 | $75.9M | $289.0M | ||
| Q1 25 | $-64.5M | $684.0M | ||
| Q4 24 | $312.6M | $164.0M | ||
| Q3 24 | $42.2M | $151.0M | ||
| Q2 24 | $9.5M | $390.0M | ||
| Q1 24 | $-1.4M | $522.0M |
自由现金流PRGOUGI
| Q4 25 | $148.6M | $-155.0M | ||
| Q3 25 | $29.8M | $-168.0M | ||
| Q2 25 | $56.7M | $67.0M | ||
| Q1 25 | $-90.0M | $538.0M | ||
| Q4 24 | $274.9M | $-47.0M | ||
| Q3 24 | $15.1M | $-115.0M | ||
| Q2 24 | $-18.9M | $185.0M | ||
| Q1 24 | $-26.5M | $353.0M |
自由现金流率PRGOUGI
| Q4 25 | 13.4% | -7.5% | ||
| Q3 25 | 2.9% | -14.4% | ||
| Q2 25 | 5.4% | 4.9% | ||
| Q1 25 | -8.6% | 20.4% | ||
| Q4 24 | 24.2% | -2.4% | ||
| Q3 24 | 1.4% | -9.5% | ||
| Q2 24 | -1.8% | 13.7% | ||
| Q1 24 | -2.4% | 14.6% |
资本支出强度PRGOUGI
| Q4 25 | 2.4% | 10.7% | ||
| Q3 25 | 2.1% | 22.1% | ||
| Q2 25 | 1.8% | 16.3% | ||
| Q1 25 | 2.4% | 5.5% | ||
| Q4 24 | 3.3% | 10.6% | ||
| Q3 24 | 2.5% | 22.0% | ||
| Q2 24 | 2.7% | 15.2% | ||
| Q1 24 | 2.3% | 7.0% |
现金转化率PRGOUGI
| Q4 25 | — | 0.22× | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | 1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
UGI
暂无分部数据
